SGO 2022 Conference Coverage on VuMedi


 

SGO 2022 on Clinical Outcomes of Ovarian Cancer Patients Treated With the Novel Engineered Cytokine Nemvaleukin Alfa + Pembro: Recent Data From ARTISTRY-1

246 views
April 1, 2022
Comments 0
Login to view comments. Click here to Login